Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Species Distribution and Antifungal Susceptibility Profile of Candida species and Cryptococcus neoformans isolates : Two Years of Croatian Surveillance (CROSBI ID 587894)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Mlinarić-Missoni, Emilija ; Vazić-Babić, Verica ; Missoni, Eduard Species Distribution and Antifungal Susceptibility Profile of Candida species and Cryptococcus neoformans isolates : Two Years of Croatian Surveillance // Mycoses. 2009. str. 29-30

Podaci o odgovornosti

Mlinarić-Missoni, Emilija ; Vazić-Babić, Verica ; Missoni, Eduard

engleski

Species Distribution and Antifungal Susceptibility Profile of Candida species and Cryptococcus neoformans isolates : Two Years of Croatian Surveillance

Objectiveswere to conduct a prospective surveillance of species distribution and in vitro susceptibility to 5-fluorocitosine (5-FC), amphotericin B (AMB), fluconazole (FLU), itraconazole (ITR), and voriconazole (VOR) among Candida species and Cryptococcus neoformans isolates associated with deep–seated and disseminated infections during a 24 month-period in patients from seven Croatian medical institutions. From January 2007 to December 2008, we are able to collect a total of 685 yeast isolates: 650 (95%) isolates of 13 Candida species and 35 (5%) isolates of C. neoformans from five tertiary care hospitals, one general hospital and Croatian National Institute of Public Health (CNIPH). The isolates were collected at the individual study sites and were sent to the National Reference Laboratory for systemic mycoses (in CNIPH) for identification and susceptibility testing. Yeast isolates were identified by ID 32 C (BioMerieux) and classical methods. Antifungal susceptibility profile of isolates was determined by ATB FUNGUS 3 (BioMerieux) microdilution methods following the manufacturer's instructions. MIC readings were performed visually and the results were interpreted according to the CLSI recommendations. The collection included 115 (16.8%) bloodstream or CSF isolates of Candida species and C. neoformans and 570 (83.2%) isolates of Candida species from other clinical samples (BAL, sputum, urine, aspirates, drainage swabs, stools). Candida species distribution was as follows: C. albicans 360 (55%), C. glabrata 110 (17%), C. parapsilosis 63 (10%), C. krusei 35 (5%), C. tropicalis 25 (4%) and the other Candida species 57 (9%). Only 0.3% C. albicans and 8.6% C. krusei isolates were resistant to 5-FC. All Candida species and C. neoformans isolates were sensitive to AMB. Isolates of C. albicans, C. tropicalis, and C. neoformans were all susceptible to FLU, whereas 82.5% C. glabrata, 88.9% C. parapsilosis, 0% C. krusei, and 97.8% of the other tested Candida species isolates were susceptible to this antifungal agent. Intermediate susceptibility and resistance against ITR were found for 68.2% C. glabrata, 31.7% C. parapsilosis, 94.3% C. krusei, and 20% of the other tested Candida species isolates. Resistance to VOR was detected in 4 (11.4%) C. krusei isolates. The results of the two years of Croatian antifungal susceptibility surveillance showed the existence of different frequency of isolation pattern and antifungal susceptibility profile in yeast isolates among institutions. C. albicans account for approximately one-half of all clinical isolates, and the most (99.7%) of our C. albicans isolates remained susceptible to all antifungal drug tested. We were able to demonstrate that in Croatia most non-albicans Candida species are represented by C. glabrata, C. parapsilosis, C. krusei, and C. tropicalis isolates still susceptible to 5-FC, AMB and VOR. Conversely, non-albicans Candida spp. isolates have higher intermediate and resistance rates to FLU and ITR, the second generation of systemic triazoles. The overall susceptibility of C. neoformans isolates was 100% for all antifungals tested. However, continuous surveillance programs are needed in order to identify possible changes in the species distribution and antifungal susceptibility patterns of yeasts, particularly after increasing the use of triazoles in Croatian hospitals.

Candida species; Cryptococcus neoformans; clinical isolates; antifungal susceptibilities; Croatia

DOI: 10.1111/j.1439-0507.2009.01782.x

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

29-30.

2009.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Mycoses

0933-7407

Podaci o skupu

Trends in Medical Mycology (4 ; 2009)

poster

18.10.2009-21.10.2009

Atena, Grčka

Povezanost rada

Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita

Indeksiranost